Structure-based characterization of novel TRPV5 inhibitors
- University of Pennsylvania, United States
- New Jersey Medical School, Rutgers University, United States
- Icahn School of Medicine at Mount Sinai, United States
Abstract
Transient receptor potential vanilloid 5 (TRPV5) is a highly calcium selective ion channel that acts as the rate-limiting step of calcium reabsorption in the kidney. The lack of potent, specific modulators of TRPV5 has limited the ability to probe the contribution of TRPV5 in disease phenotypes such as hypercalcemia and nephrolithiasis. Here, we performed structure-based virtual screening (SBVS) at a previously identified TRPV5 inhibitor binding site coupled with electrophysiology screening and identified three novel inhibitors of TRPV5, one of which exhibits high affinity, and specificity for TRPV5 over other TRP channels, including its close homologue TRPV6. Cryo-electron microscopy of TRPV5 in the presence of the specific inhibitor and its parent compound revealed novel binding sites for this channel. Structural and functional analysis have allowed us to suggest a mechanism of action for the selective inhibition of TRPV5 and lay the groundwork for rational design of new classes of TRPV5 modulators.
Data availability
The cryo-EM density maps and atomic coordinates of all structures presented in the text will be deposited into the Electron Microscopy Data Bank and Protein Data Bank under the following access codes: ZINC9155420-bound TRPV5 (PDB: 6PBF, EMB-20292); ZINC17988990-bound TRPV5 (PDB: 6PBE, EMB-20291).
-
ZINC9155420-bound TRPV5 in nanodiscsElectron Microscopy Data Bank, EMD-20292.
-
ZINC17988990-bound TRPV5 in nanodiscsElectron Microscopy Data Bank, EMD-20291.
Article and author information
Author details
John Smith Del Rosario
Aysenur Torun Yazici
Vera Y Moiseenkova-Bell
Funding
National Institute of General Medical Sciences (R01GM103899)
- Vera Y Moiseenkova-Bell
National Institute of General Medical Sciences (R01GM129357)
- Vera Y Moiseenkova-Bell
National Institute of General Medical Sciences (R01GM093290)
- Tibor Rohacs
National Institute of General Medical Sciences (R01GM131048)
- Tibor Rohacs
National Institute of Neurological Disorders and Stroke (R01NSNS055159)
- Tibor Rohacs
National Science Foundation (ACI-1053575)
- Marta Filizola
National Science Foundation (MCB080077)
- Marta Filizola
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2019, Hughes et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,602
- views
-
- 605
- downloads
-
- 48
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Structure-based characterization of novel TRPV5 inhibitors
eLife 8:e49572.
https://doi.org/10.7554/eLife.49572
Further reading
-
- Structural Biology and Molecular Biophysics
Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor transcription factor that regulates gene expression programs in response to ligand binding. Endogenous and synthetic ligands, including covalent antagonist inhibitors GW9662 and T0070907, are thought to compete for the orthosteric pocket in the ligand-binding domain (LBD). However, we previously showed that synthetic PPARγ ligands can cooperatively cobind with and reposition a bound endogenous orthosteric ligand to an alternate site, synergistically regulating PPARγ structure and function (Shang et al., 2018). Here, we reveal the structural mechanism of cobinding between a synthetic covalent antagonist inhibitor with other synthetic ligands. Biochemical and NMR data show that covalent inhibitors weaken—but do not prevent—the binding of other ligands via an allosteric mechanism, rather than direct ligand clashing, by shifting the LBD ensemble toward a transcriptionally repressive conformation, which structurally clashes with orthosteric ligand binding. Crystal structures reveal different cobinding mechanisms including alternate site binding to unexpectedly adopting an orthosteric binding mode by altering the covalent inhibitor binding pose. Our findings highlight the significant flexibility of the PPARγ orthosteric pocket, its ability to accommodate multiple ligands, and demonstrate that GW9662 and T0070907 should not be used as chemical tools to inhibit ligand binding to PPARγ.
-
- Biochemistry and Chemical Biology
- Structural Biology and Molecular Biophysics
Dynamic conformational and structural changes in proteins and protein complexes play a central and ubiquitous role in the regulation of protein function, yet it is very challenging to study these changes, especially for large protein complexes, under physiological conditions. Here, we introduce a novel isobaric crosslinker, Qlinker, for studying conformational and structural changes in proteins and protein complexes using quantitative crosslinking mass spectrometry. Qlinkers are small and simple, amine-reactive molecules with an optimal extended distance of ~10 Å, which use MS2 reporter ions for relative quantification of Qlinker-modified peptides derived from different samples. We synthesized the 2-plex Q2linker and showed that the Q2linker can provide quantitative crosslinking data that pinpoints key conformational and structural changes in biosensors, binary and ternary complexes composed of the general transcription factors TBP, TFIIA, and TFIIB, and RNA polymerase II complexes.
